These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25684663)

  • 21. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells.
    Zitzmann K; de Toni E; von Rüden J; Brand S; Göke B; Laubender RP; Auernhammer CJ
    Endocr Relat Cancer; 2011 Apr; 18(2):277-85. PubMed ID: 21317202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
    Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
    Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
    Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
    Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
    Zhang T; Wang X; He D; Jin X; Guo P
    Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
    Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
    Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
    Ryu YL; Jung KH; Son MK; Yan HH; Kim SJ; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Oct; 353(1):68-77. PubMed ID: 25016056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
    Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
    Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
    Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition.
    Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C
    Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells.
    Lee TJ; Jang JH; Noh HJ; Park EJ; Choi KS; Kwon TK
    J Cell Biochem; 2010 Apr; 109(5):885-95. PubMed ID: 20127709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G; Zhan Y; Wang H; Li W
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
    Ding J; Polier G; Köhler R; Giaisi M; Krammer PH; Li-Weber M
    J Biol Chem; 2012 Jan; 287(1):641-649. PubMed ID: 22086925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells.
    Palacios C; Yerbes R; López-Rivas A
    Cancer Res; 2006 Sep; 66(17):8858-69. PubMed ID: 16951203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
    Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
    Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
    J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.